A multipronged approach involving different cardiac biomarkers, particularly troponins, remains the best strategy for the timely diagnosis and management of acute coronary syndrome.
Cardiac biomarkers are of great importance in the timely, accurate diagnosis and management of acute coronary syndrome as well as the prognosis. Diagnosis in the golden period is of utmost importance to institute therapy at the earliest and possibly reverse the myocardial damage. Cardiac biomarkers are also a powerful tool for triaging. Among the many biomarkers, the earliest examined were the myocardial enzymes, several myocardial proteins, peptides, and many other molecules. The latest addition to the repertoire is the microRNAs, which are stable molecules detectable in circulation. About four groups are found to be involved in regulation of circulatory system, and some show promise as specific and early markers of acute coronary syndrome and cardiac dysfunction. As in other fields of medicine, personalized precise treatment may be possible with the use of microRNAs. However, as of now, a multipronged approach, involving different markers of which troponins are necessary, seems to be the best way forward.
Jacob et al. (Sat,) conducted a review in Acute coronary syndrome. Cardiac biomarkers was evaluated. A multipronged approach involving different cardiac biomarkers, particularly troponins, remains the best strategy for the timely diagnosis and management of acute coronary syndrome.